期刊
BREAST CARE
卷 12, 期 5, 页码 304-308出版社
KARGER
DOI: 10.1159/000484167
关键词
CDK4/6 inhibitors; Drug resistance; Breast cancer
资金
- AIRC (Associazione Italiana per la Ricerca sul Cancro)
- Fondazione 'Sandro Pitigliani' per la lotta contro i tumori ONLUS
Randomized clinical trials demonstrated that CDK4/6 inhibitors are highly effective in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer in combination with endocrine therapy. The use of CDK4/6 inhibitors in clinics is becoming common for patients with HR+/HER2- metastatic breast cancer and will certainly increase in the near future. However, patients might show de novo or acquired resistance to these drugs. Molecular alterations have been suggested as determinants for de novo resistance to CDK4/6 inhibitors, but have never been validated in a clinical setting. In addition, molecular mechanisms of acquired resistance to palbociclib have been analyzed only in preclinical studies. Here we review the current knowledge on the available preclinical data about the mechanisms of de novo and acquired resistance to CDK4/6 inhibitors in breast cancer, and clinical data about potential biomarkers of response. (C) 2017 The Author(s). Published by S. Karger GmbH, Freiburg
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据